Data on long haul treatment November 2022

Here is an overview of the latest data on long haul treatment.

• Video presentation (45 minutes, less if played at 2X speed)
• Slides only

Highlights:

• The most promising treatments out of 100+ interventions surveyed.
• What high-quality data tells us about HBOT, leronlimab (related to maraviroc), and rituximab.
• Treatments that seems to be causing more harm than good.

Updates:

• An analysis of targeted treatment for food intolerances and some other specific symptoms.
• An expanded discussion on what effective treatment would look like.